Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying Regeneron’s motion for a preliminary injunction in the company’s aflibercept patent litigation against Amgen (AMGN), but a decision posted by the United States Court of Appeals for the Federal Circuit, dated March 14, indicates that the appeals court affirms the lower court’s judgement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi presents results from ADEPT Phase 2/3 trial on Dupixent
- Regeneron’s treatment of lipodystrophy granted FDA orphan designation
- Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
- 3 Best Value Stocks to Buy Now, 2/27/2025, According to Analysts
- REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.